Results 151 to 160 of about 101,080 (259)
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou +16 more
wiley +1 more source
Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree +9 more
wiley +1 more source
Film review: 28 Years Later: The Bone Temple. [PDF]
Heer-Stavert S.
europepmc +1 more source
Structures, strategies and beyond : studies in honour of Adriana Belletti
E. D. Domenico +2 more
semanticscholar +1 more source
Prominent Movement Disorders in RNU2‐2‐Related Spliceosomopathy
ABSTRACT Pediatric movement disorders often overlap with neurodevelopmental diseases, suggesting shared molecular mechanisms. Variants in small nuclear RNA (snRNA) genes encoding spliceosome components have recently been associated with neurodevelopmental disorders, termed “RNUopathies.” We analyzed genome sequencing data from 14 patients with ...
Magdalena Krygier +6 more
wiley +1 more source
Proposal of <i>Allobrachymonas</i> gen. nov. and three new combinations as replacement names for the illegitimate prokaryotic genus name <i>Brachymonas</i>, proposal of <i>Allobosea</i> gen. nov. and 12 new combinations as replacement names for the illegitimate prokaryotic genus name <i>Bosea</i> and proposal of <i>Alloboseaceae</i> fam. nov. as a replacement name for the illegitimate family name <i>Boseaceae</i>. [PDF]
Deshmukh UB, Oren A.
europepmc +1 more source
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers +19 more
wiley +1 more source

